SCHEMBL7140664

SCHEMBL7140664

COc1ccc(-c2c[nH]c(-c3ccccc3)n2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.54
AMY1A P0DUB6 3/20 0.47
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NFKB1 P19838 3/20 0.46
NFKB2 Q00653 3/20 0.46
RELA Q04206 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GRM2 Q14416 1/20 0.43
CHRNA7 P36544 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
NR1H2 P55055 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8111883 0.91 PDGFRB (0.47) PDGFRBAMY1ANPC1RAB9ASMN1; SMN2
SCHEMBL7144910 0.90 PDGFRB (0.54) PDGFRBAMY1ANPC1RAB9ATP53
SCHEMBL7135114 0.86 LMNA (0.49) PDGFRBNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL8119559 0.85 AURKA (0.43) PDGFRBAMY1ANPC1RAB9AMEN1
SCHEMBL29212567 0.83 ADORA1 (0.43) PDGFRBNPC1RAB9ATP53MEN1
SCHEMBL8118299 0.82 PDGFRB (0.43) PDGFRBNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL7146244 0.80 NR1H2 (0.58) PDGFRBNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL8124257 0.80 PDGFRB (0.41) PDGFRBNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL8123906 0.79 PDGFRB (0.41) PDGFRBNPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL650259 0.79 NPC1 (0.51) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed